Pfizer
Biopharmaceutical company develops medicines and vaccines
Senior Oncology Account Specialist - Hematology
+ Sales incentive bonus
More locations: Atlanta, GA, USA
Territory includes Atlanta, Rome, and Northern Georgia; domestic travel and overnight stays are required. Relocation assistance may be available.
About the job
- A BA/BS degree from an accredited institution, or an associate’s degree with 8+ years of experience, or a high school diploma or equivalent with 10+ years of relevant experience.
- Ability to travel domestically and stay overnight as necessary.
- A valid United States driver’s license and a driving record that complies with company standards; any DUI/DWI or other impaired-driving citation within the past seven years disqualifies the candidate.
- At least four years of pharmaceutical sales experience or at least four years of oncology healthcare professional experience working with key oncology thought leaders or high-influence customers in hospitals, large group practices, or managed care organizations.
- A demonstrated track record of success and accomplishment in pharmaceutical sales or healthcare professional experience.
- Ability to learn and communicate technical and scientific product and disease-management information to a wide range of customers.
- A high degree of business acumen.
- Proficiency with complex digital applications and ability to adapt to Pfizer’s long-range technology model for bringing relevant Pfizer information to market.
- Permanent authorization to work in the United States.
- Promote Pfizer’s broad product portfolio to healthcare providers and specialists.
- Educate members of the healthcare community regarding the appropriate use of Pfizer products.
- Call on accounts and organized customers to improve patients’ experience with Pfizer products and the overall quality of patient care.
- Increase Pfizer’s brand presence with high-value target customers by linking insightful assessments of account and business landscapes with a strong understanding of Pfizer products and resources.
- Generate demand for Pfizer products in assigned accounts.
- Develop comprehensive territory, account, and customer plans to achieve desired objectives.
- Maintain relationships throughout institutions.
- Overcome obstacles to gain access to difficult-to-see healthcare providers and customers.
- Cultivate relationships with key opinion leaders and build lasting relationships with priority customers.
- Assess the needs of target physicians and accounts and address them with a responsive approach, targeted skills, and appropriate resources.
- Engage, influence, and support customers throughout the selling process.
- Work in a matrix environment and leverage multiple resources to meet customer needs and deliver results.
- Three to five years of oncology sales experience.
- Experience in the hematology therapeutic area.
- A master’s degree.
- An advanced healthcare professional degree.
- Experience calling on institutions, National Cancer Institute centers, and key opinion leaders.
- Strong knowledge of disease states, therapeutic areas, and products.
- Deep knowledge of applicable customers and markets, including prescribers, healthcare professionals, institutions, and organizations.
- Strategic account selling and management skills.
- Superior selling, technical, and relationship-building skills.
- Ability to quickly learn and embrace new ways of working in a rapidly changing environment.
About the company
Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.
Company Size
10,001+
Company Stage
IPO
Headquarters
New York City, New York
Founded
1849
Get referred to Pfizer
See people who can refer or advise you
Simplify's Take
What believers are saying
- August 27, 2026 FDA approval relaunched Comirnaty XFG for the fall vaccine season.
- Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on stronger non-COVID products.
- 2026 obesity and oncology catalysts include berobenatide, atirmociclib, and sigvotatug vedotin.
What critics are saying
- Eliquis patent expiry in 2028 and Ibrance in 2027 crushes 2027-2030 revenue.
- September 2026 FDA limits Comirnaty XFG to seniors and high-risk patients, shrinking demand.
- Generic pricing antitrust suits and manufacturing cuts in Ireland expose operational strain.
What makes Pfizer unique
- Pfizer pairs global scale with BioNTech mRNA manufacturing and distribution reach.
- Eliquis, Padcev, and Vyndaqel offset aging COVID revenue and fund the transition.
- Pfizer can run late-stage oncology and obesity programs simultaneously, unlike smaller biotechs.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
401(k) Company Match
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↓ -5%1 year growth
↓ -5%2 year growth
↓ -5%Pfizer's chief executive Albert Bourla says the pharmaceutical company's major headwinds are easing. Speaking at a recent conference, Bourla identified three challenges facing the drugmaker in 2025: tariffs and drug pricing policies, declining coronavirus product sales, and patent cliffs. The company has addressed tariffs by signing agreements with the US government for reduced medicine prices in exchange for tariff breaks. Pfizer has exceeded Wall Street's earnings-per-share estimates in all 10 of its past quarterly reports, suggesting its coronavirus business no longer significantly impacts performance. However, major patent cliffs loom. Eliquis, which generated $4.6 billion in the first half of the year, could face generic competition by 2028. Cancer treatment Ibrance, with $2.1 billion in first-half revenue, faces US patent expiration in 2027. Pfizer has cut $7.2 billion in costs and expanded its pipeline through acquisitions and internal development, with new products generating $13 billion annually. The company offers a 6.2% dividend yield.
Medicus Pharma has secured a development and licensing agreement with Pfizer for a CD228-targeted antibody-drug conjugate programme focused on solid tumours, including refractory melanoma. Pfizer is providing approximately $2 million in development funding, plus inventory and infrastructure support. CEO Dr Raza Bokhari said the deal allows Medicus to continue from where Pfizer concluded its Phase 1 dose-escalation work, strengthening the company's position in precision oncology. Medicus is also advancing its SkinJect programme for basal cell carcinoma. Final clinical trial results identified the 200-microgram patch as the optimal dose for future studies. The company is preparing for the FDA-approved pivotal SkinJect 005 study whilst recruiting patients. An independent reimbursement analysis suggests SkinJect could achieve reimbursement levels of $25,000 or more per patient.
AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.
Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.
Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.